Latest Hemiparesis Stories

ROCKVILLE, Md., July 25, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the seventeenth patient was treated in the ongoing Phase I trial of its spinal cord neural stem cells for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). This patient is also the second to return to the trial for additional injections. In this treatment, the patient received five injections in the cervical (upper back) region of the spinal cord, in addition to...

ROCKVILLE, Md., June 19, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient to receive stem cell transplantation in both regions of the spinal cord has been treated in the ongoing Phase I trial of its spinal cord neural stem cells in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). This is also the 16th patient to be treated in the trial altogether and the first patient returning to the trial for a second treatment. In this treatment,...

[ Watch the Video ] Connie K. Ho for RedOrbit.com Surgeons at Washington State University in St. Louis recently revealed that they were able to restore some hand function in a quadriplegic patient who suffered from a spinal cord injury at the C7 Vertebra, which is the lowest bone in the neck. They were able to reroute the working nerves in the arms instead of operating on the spine. The nerves are able to communicate with the brain because they’re attached to the part of the spine...

Cervical spine CT examinations are unnecessary for emergency department (ED) patients who are a victim of "simple assault" or who have a "ground-level fall", unless the patient has a condition that predisposes the patient to spine fracture, a new study finds. The study, conducted at Grady Memorial Hospital by researchers from the Department of Radiology and Imaging Sciences of the Emory University School of Medicine in Atlanta, found that out of 218 exams for simple assault, there were...

PARAMUS, N.J., April 23, 2012 /PRNewswire/ -- Today, Asubio announced the initiation of a landmark Phase 2 clinical trial of SUN13837, an investigational medication being developed to improve neurological function in patients with newly diagnosed acute spinal cord injury. In accordance with its internal focus on scientific rigor, Asubio recently discussed its endpoint development activities at a peer-attended symposium at the American Spinal Injury Association (ASIA) annual...

Researchers at the Rothman Institute at Jefferson have shown that patients who receive surgery less than 24 hours after a traumatic cervical spine injury suffer less neural tissue destruction and improved clinical outcomes. The results of their study, the Surgical Timing in Acute Spinal Cord Injury Study (STASCIS) are available in PLoS One. PHILADELPHIA (PRWEB) March 26, 2012 Researchers at the Rothman Institute at Jefferson have shown that patients who receive surgery less than 24 hours...

Researchers at the Rothman Institute at Jefferson have shown that patients who receive surgery less than 24 hours after a traumatic cervical spine injury suffer less neural tissue destruction and improved clinical outcomes. The results of their study, the Surgical Timing in Acute Spinal Cord Injury Study (STASCIS) are available in PLoS One. "This practice-changing study is the first to show that the timing of surgery after traumatic spinal cord injury (SCI) matters," says Alexander...

The American Academy of Neurology is issuing an updated guideline that recommends monitoring the spinal cord during spinal surgery and certain chest surgeries to help prevent paralysis, or loss of muscle function, related to the surgeries. The guideline, which was developed with the American Clinical Neurophysiology Society, is published in the February 21, 2012, print issue of Neurology®, the medical journal of the American Academy of Neurology and also in the Journal of Clinical...

ROCKVILLE, Md., Nov. 23, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that the first patient to receive stem cells in the cervical (upper back) region of the spine was treated on Friday in its ongoing trial to test the safety of its spinal cord neural stem cells in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). Patient 13 is the first in the trial to be dosed in this region. It is also the first time surgeons have gone into the gray matter of the...

  Kris Appel's company, Encore Path, Inc., markets a new device that stimulates and encourages rewiring of the brain, helping stroke victims recover from partial paralysis Kris Appel was a federal employee for 17 years, working for the National Security Agency, when she realized she wanted to join the ranks of America's entrepreneurs. Thanks to a program designed to bring scientists and engineers together with small business owners, Appel launched a new company that is now bringing...